$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

$nwbo Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000141057824000133 Filed on March 05, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$284.0K	$445.0K	$1.932M
YoY Change	-67.73%	-25.46%	14.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.086M	$8.133M	$29.71M
YoY Change	15.8%	-13.69%	-10.92%
% of Gross Profit
Research & Development	$7.942M	$7.454M	$27.73M
YoY Change	15.76%	-20.3%	-21.91%
% of Gross Profit
Depreciation & Amortization	$400.0K	$425.0K	$1.500M
YoY Change	33.33%	33.65%	15.38%
% of Gross Profit
Operating Expenses	$7.942M	$15.59M	$27.73M
YoY Change	15.76%	-16.98%	-21.91%
Operating Profit	-$15.74M		-$55.51M
YoY Change	21.44%		-17.38%
Interest Expense	$1.518M	-$1.000K	$5.241M
YoY Change	47.81%	-99.99%	-13.63%
% of Operating Profit
Other Income/Expense, Net	-$2.568M	-$2.021M	-$7.091M
YoY Change	-211.07%		-81.27%
Pretax Income	-$18.31M	-$18.92M	-$62.60M
YoY Change	71.91%	-33.14%	-40.4%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$18.31M	-$19.26M	-$62.60M
YoY Change	71.14%	-31.94%	-40.38%
Net Earnings / Revenue	-6447.89%	-4328.09%	-3240.11%
Basic Earnings Per Share	-$0.02		-$0.06
Diluted Earnings Per Share	-$0.02	-$0.02	-$0.06
COMMON SHARES
Basic Shares Outstanding	1.190B	1.154B	1.119M
Diluted Shares Outstanding	1.188M		1.119M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.478M	$2.126M	$2.126M
YoY Change	-59.97%	-69.48%	-69.48%
Cash & Equivalents	$2.478M	$2.126M	$2.126M
Short-Term Investments
Other Short-Term Assets	$2.470M	$1.999M	$1.999M
YoY Change	-25.15%	-18.74%	-18.74%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.948M	$4.125M	$4.125M
YoY Change	-47.87%	-56.23%	-56.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.27M	$17.28M	$21.46M
YoY Change	27.25%	28.77%	9.3%
Goodwill	$626.0K	$626.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$363.0K	$361.0K	$361.0K
YoY Change	0.28%	4.64%	4.64%
Total Long-Term Assets	$23.62M	$23.74M	$23.74M
YoY Change	1.02%	8.41%	8.41%
TOTAL ASSETS
Total Short-Term Assets	$4.948M	$4.125M	$4.125M
Total Long-Term Assets	$23.62M	$23.74M	$23.74M
Total Assets	$28.57M	$27.87M	$27.87M
YoY Change	-13.09%	-11.04%	-11.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.82M	$13.79M	$13.79M
YoY Change	-13.63%	-21.85%	-21.85%
Accrued Expenses	$245.0K	$314.0K	$314.0K
YoY Change	-33.6%	-11.3%	-11.3%
Deferred Revenue
YoY Change
Short-Term Debt	$5.612M	$3.765M	$3.765M
YoY Change	4057.04%	2688.89%	2688.89%
Long-Term Debt Due	$28.62M	$16.72M	$16.72M
YoY Change	173.34%	8.52%	8.52%
Total Short-Term Liabilities	$62.44M	$45.20M	$45.20M
YoY Change	39.66%	-64.13%	-64.13%
LONG-TERM LIABILITIES
Long-Term Debt	$10.22M	$20.31M	$20.31M
YoY Change	-36.23%	239.04%	239.04%
Other Long-Term Liabilities	$9.384M	$9.404M	$9.404M
YoY Change	114.74%	115.19%	115.19%
Total Long-Term Liabilities	$19.60M	$29.72M	$29.72M
YoY Change	-3.87%	186.81%	186.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$62.44M	$45.20M	$45.20M
Total Long-Term Liabilities	$19.60M	$29.72M	$29.72M
Total Liabilities	$82.04M	$74.92M	$74.92M
YoY Change	26.03%	-45.06%	-45.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.378B	-$1.360B
YoY Change	5.37%	4.83%
Common Stock	$1.303B	$1.292B
YoY Change	4.26%	10.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$73.28M	-$65.77M	-$47.06M
YoY Change
Total Liabilities & Shareholders Equity	$28.57M	$27.87M	$27.87M
YoY Change	-13.09%	-11.04%	-11.04%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$18.31M	-$19.26M	-$62.60M
YoY Change	71.14%	-31.94%	-40.38%
Depreciation, Depletion And Amortization	$400.0K	$425.0K	$1.500M
YoY Change	33.33%	33.65%	15.38%
Cash From Operating Activities	-$12.41M	-$16.96M	-$53.64M
YoY Change	10.38%	91.63%	1.63%
INVESTING ACTIVITIES
Capital Expenditures	$239.0K	$417.0K	$3.437M
YoY Change	-82.07%	-80.69%	18.44%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$239.0K	-$417.0K	-$3.437M
YoY Change	-82.07%	-80.69%	18.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.09M	14.42M	52.76M
YoY Change	-3.95%	27.02%	25.71%
NET CHANGE
Cash From Operating Activities	-12.41M	-16.96M	-53.64M
Cash From Investing Activities	-239.0K	-417.0K	-3.437M
Cash From Financing Activities	12.09M	14.42M	52.76M
Net Change In Cash	352.0K	-2.956M	-4.839M
YoY Change	-145.48%	-964.33%	-41.02%
FREE CASH FLOW
Cash From Operating Activities	-$12.41M	-$16.96M	-$53.64M
Capital Expenditures	$239.0K	$417.0K	$3.437M
Free Cash Flow	-$12.65M	-$17.37M	-$57.07M
YoY Change	0.58%	57.82%	2.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001072379
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Security Exchange Name SecurityExchangeName	NONE
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1068400000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1175500000
CY2022	us-gaap	Fair Value Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#DerivativeGainLossOnDerivativeNet
CY2023	us-gaap	Fair Value Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List FairValueLiabilityRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#DerivativeGainLossOnDerivativeNet
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-64373000
CY2023	us-gaap	Sublease Income SubleaseIncome	144000
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P20Y
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-35737
CY2023	dei	Entity Registrant Name EntityRegistrantName	NORTHWEST BIOTHERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3306718
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4800 Montgomery Lane
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 800
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Bethesda
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20814
CY2023	dei	City Area Code CityAreaCode	240
CY2023	dei	Local Phone Number LocalPhoneNumber	497-9024
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	NWBO
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	617219000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1189970308
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	677
CY2023	dei	Auditor Name AuditorName	Cherry Bekaert LLP
CY2023	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2126000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6965000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1999000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2460000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4125000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	9425000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17278000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13418000
CY2022Q4	nwbo	Constructions In Progress Net ConstructionsInProgressNet	2028000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4183000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4189000
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1292000
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1292000
CY2023Q4	us-gaap	Goodwill Goodwill	626000
CY2022Q4	us-gaap	Goodwill Goodwill	626000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	361000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	345000
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	23740000
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	21898000
CY2023Q4	us-gaap	Assets Assets	27865000
CY2022Q4	us-gaap	Assets Assets	31323000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10244000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10687000
CY2023Q4	nwbo	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	3544000
CY2022Q4	nwbo	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	6955000
CY2023Q4	nwbo	Convertible Notes Payable Net Current ConvertibleNotesPayableNetCurrent	3765000
CY2022Q4	nwbo	Convertible Notes Payable Net Current ConvertibleNotesPayableNetCurrent	135000
CY2023Q4	nwbo	Convertible Notes At Fair Value Current ConvertibleNotesAtFairValueCurrent	12771000
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	3944000
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	15403000
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	9188000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	8668000
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	944000
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	80559000
CY2023Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	7000
CY2022Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2566000
CY2023Q4	nwbo	Share Liability ShareLiability	483000
CY2022Q4	nwbo	Share Liability ShareLiability	678000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	314000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	354000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45204000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	126005000
CY2021	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	4070000
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	68864000
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	53707000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-55508000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-67181000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-52702000
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	3644000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-25821000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	239347000
CY2023	nwbo	Fair Value Adjustment Of Share Liability FairValueAdjustmentOfShareLiability	-78000
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	20312000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	5991000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4454000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4370000
CY2023Q4	nwbo	Contingent Payment Obligation Noncurrent ContingentPaymentObligationNoncurrent	4950000
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	29716000
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10361000
CY2023Q4	us-gaap	Liabilities Liabilities	74920000
CY2022Q4	us-gaap	Liabilities Liabilities	136366000
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	18718000
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	23060000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1700000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1700000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1175500000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1068400000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1175000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1068000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1291316000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1164885000
CY2023Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	79000
CY2022Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	79000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1359721000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1297122000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1536000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3145000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-65773000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-128103000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27865000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31323000
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1932000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1683000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1005000
CY2023	us-gaap	Revenues Revenues	1932000
CY2022	us-gaap	Revenues Revenues	1683000
CY2021	us-gaap	Revenues Revenues	1005000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27730000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35511000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20308000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29710000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33353000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33399000
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	57440000
CY2022	nwbo	Fair Value Adjustment Of Share Liability FairValueAdjustmentOfShareLiability	33000
CY2023	nwbo	Fair Value Adjustment Of Convertible Notes FairValueAdjustmentOfConvertibleNotes	-2021000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5403000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2691000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-165000
CY2023	us-gaap	Interest Expense InterestExpense	5241000
CY2022	us-gaap	Interest Expense InterestExpense	6068000
CY2021	us-gaap	Interest Expense InterestExpense	5011000
CY2021	nwbo	Inducement Expense InducementExpense	647000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	2008000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-3304000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-1696000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7091000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-37851000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	231828000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-62599000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-105032000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	179126000
CY2023	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	1774000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-64373000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-105032000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	179126000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	1609000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-2788000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1505000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-65982000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102244000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	180631000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.21
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1119191
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1015852
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	873517
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1119191
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1015852
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1007869
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-362948000
CY2021	nwbo	Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest	7500000
CY2021	nwbo	Value Of Warrants And Stock Options Exercised For Cash ValueOfWarrantsAndStockOptionsExercisedForCash	19975000
CY2021	nwbo	Adjustments To Additional Paid In Capital Reclassification AdjustmentsToAdditionalPaidInCapitalReclassification	68692000
CY2021	nwbo	Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise	2369000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15571000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	179126000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1505000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-123991000
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	9689000
CY2022	nwbo	Value Of Warrants Exercised For Cash ValueOfWarrantsExercisedForCash	11105000
CY2022	nwbo	Adjustments To Additional Paid In Capital Reclassification AdjustmentsToAdditionalPaidInCapitalReclassification	24434000
CY2022	nwbo	Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise	26800000
CY2022	nwbo	Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest	13806000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12298000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-105032000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2788000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-128103000
CY2023	nwbo	Value Of Warrants Exercised For Cash ValueOfWarrantsExercisedForCash	2920000
CY2023	nwbo	Adjustments To Additional Paid In Capital Reclassification AdjustmentsToAdditionalPaidInCapitalReclassification	76258000
CY2023	nwbo	Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest	24652000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4178000
CY2023	nwbo	Adjustments To Additional Paid In Capital Reclass Issued Milestone Shares From Equity To Liability AdjustmentsToAdditionalPaidInCapitalReclassIssuedMilestoneSharesFromEquityToLiability	1065000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-62599000
CY2023	nwbo	Adjustments To Additional Paid In Capital Warrants Modification AdjustmentsToAdditionalPaidInCapitalWarrantsModification	2454000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	1774000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1609000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-65773000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-62599000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-105032000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	179126000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1525000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1252000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	324000
CY2023	nwbo	Amortization Of Debt Discount AmortizationOfDebtDiscount	2372000
CY2022	nwbo	Amortization Of Debt Discount AmortizationOfDebtDiscount	2771000
CY2021	nwbo	Amortization Of Debt Discount AmortizationOfDebtDiscount	2301000
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	3644000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-25821000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	239347000
CY2023	nwbo	Fair Value Adjustment Of Share Liability FairValueAdjustmentOfShareLiability	-78000
CY2022	nwbo	Fair Value Adjustment Of Share Liability FairValueAdjustmentOfShareLiability	33000
CY2023	nwbo	Fair Value Adjustment Of Convertible Notes FairValueAdjustmentOfConvertibleNotes	-2021000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5403000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2691000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-165000
CY2021	nwbo	Inducement Expense InducementExpense	647000
CY2023	nwbo	Operating Lease Roa OperatingLeaseRoa	208000
CY2022	nwbo	Operating Lease Roa OperatingLeaseRoa	248000
CY2021	nwbo	Operating Lease Roa OperatingLeaseRoa	262000
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	4408000
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	12298000
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	15498000
CY2023	nwbo	Warrant Modifications Associated With Convertible Notes Under Fair Value Option WarrantModificationsAssociatedWithConvertibleNotesUnderFairValueOption	286000
CY2023	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	12657000
CY2022	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	45048000
CY2021	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-220150000
CY2023	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-501000
CY2022	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	397000
CY2021	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-3475000
CY2023	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	12000
CY2022	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	-625000
CY2021	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	179000
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	50000
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	3492000
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	77000
CY2023	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-4476000
CY2022	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	3354000
CY2021	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-674000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	242000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	135000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	26000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53637000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52775000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38299000
CY2023	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	3437000
CY2022	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	2902000
CY2021	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	6015000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3437000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2902000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6015000
CY2023	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	13330000
CY2022	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	18669000
CY2022	nwbo	Proceeds From Issuance Of Redeemable Convertible Preferred Stock By Common Stock Warrant Exercise Net Of Debt Redemption ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockByCommonStockWarrantExerciseNetOfDebtRedemption	52000
CY2022	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	9465000
CY2021	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	4070000
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1717000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11105000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	19975000
CY2023	nwbo	Proceeds From Investor Advance ProceedsFromInvestorAdvance	7000
CY2022	nwbo	Proceeds From Investor Advance ProceedsFromInvestorAdvance	2566000
CY2021	nwbo	Proceeds From Investor Advance ProceedsFromInvestorAdvance	250000
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	20000000
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5600000
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	29665000
CY2023	nwbo	Proceeds From Issuance Of Convertible Notes Payable ProceedsFromIssuanceOfConvertibleNotesPayable	13339000
CY2023	nwbo	Proceeds From Contingent Payment Obligation ProceedsFromContingentPaymentObligation	4950000
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	385000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5489000
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5828000
CY2023	nwbo	Repayment Of Investor Advances RepaymentOfInvestorAdvances	200000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52758000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41968000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48132000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-523000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5505000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1368000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4839000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8204000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5186000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6965000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15169000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9983000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2126000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6965000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15169000
CY2023	nwbo	Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise	21000
CY2022	nwbo	Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise	34000
CY2021	nwbo	Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise	20000
CY2022	nwbo	Reclassification Of Warrant Liabilities Related To Warrants Exercised For Cash ReclassificationOfWarrantLiabilitiesRelatedToWarrantsExercisedForCash	24969000
CY2021	nwbo	Reclassification Of Warrant Liabilities Related To Warrants Exercised For Cash ReclassificationOfWarrantLiabilitiesRelatedToWarrantsExercisedForCash	68692000
CY2023	nwbo	Reclassification Of Warrant Liabilities To Stockholders Deficit Non Cash Investing And Financing Activities ReclassificationOfWarrantLiabilitiesToStockholdersDeficitNonCashInvestingAndFinancingActivities	76258000
CY2022	nwbo	Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised	26800000
CY2021	nwbo	Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised	2369000
CY2021	nwbo	Reclassification Of Warrant Liabilities Based On Authorized Shares ReclassificationOfWarrantLiabilitiesBasedOnAuthorizedShares	59851000
CY2023	nwbo	Reclassification Of Investor Advances To Convertible Notes Payable ReclassificationOfInvestorAdvancesToConvertibleNotesPayable	1163000
CY2023	nwbo	Reclassification Of Investor Advances To Stockholders Deficit ReclassificationOfInvestorAdvancesToStockholdersDeficit	1203000
CY2023	nwbo	Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived	24652000
CY2022	nwbo	Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived	11541000
CY2021	nwbo	Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived	7487000
CY2023	nwbo	Issuance Of Convertible Preferred Stock In Lieu Of Debt Redemption IssuanceOfConvertiblePreferredStockInLieuOfDebtRedemption	1013000
CY2022	nwbo	Issuance Of Convertible Preferred Stock In Lieu Of Debt Redemption IssuanceOfConvertiblePreferredStockInLieuOfDebtRedemption	3408000
CY2022	nwbo	Exercise Common Stock Warrants By Debt Redemption ExerciseCommonStockWarrantsByDebtRedemption	277000
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	18915000
CY2023	nwbo	Capital Expenditures Included In Accounts Payable CapitalExpendituresIncludedInAccountsPayable	178000
CY2022	nwbo	Capital Expenditures Included In Accounts Payable CapitalExpendituresIncludedInAccountsPayable	699000
CY2021	nwbo	Capital Expenditures Included In Accounts Payable CapitalExpendituresIncludedInAccountsPayable	33000
CY2021	nwbo	Capital Expenditures Included In Accounts Payable And Accrued Expenses To Related Parties And Affiliates CapitalExpendituresIncludedInAccountsPayableAndAccruedExpensesToRelatedPartiesAndAffiliates	370000
CY2021	nwbo	Issuance Of Common Shares To Settle Accrued Service Liability IssuanceOfCommonSharesToSettleAccruedServiceLiability	73000
CY2022	nwbo	Reclassification Between Shares Payable And Equity ReclassificationBetweenSharesPayableAndEquity	250000
CY2023	nwbo	Adjustments To Additional Paid In Capital Reclassification Of Earned But Unissued Milestone Shares From Equity To Liability AdjustmentsToAdditionalPaidInCapitalReclassificationOfEarnedButUnissuedMilestoneSharesFromEquityToLiability	1065000
CY2023	nwbo	Deemed Dividend Related To Warrant Modification Non Cash Investing And Financing Activities DeemedDividendRelatedToWarrantModificationNonCashInvestingAndFinancingActivities	1774000
CY2023	nwbo	Debt Discount Related To Warrant Modification Non Cash Investing And Financing Activities DebtDiscountRelatedToWarrantModificationNonCashInvestingAndFinancingActivities	394000
CY2023	us-gaap	Profit Loss ProfitLoss	-62800000
CY2023	us-gaap	Payments For Operating Activities PaymentsForOperatingActivities	53600000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution, which at times may exceed the Federal depository insurance coverage (“FDIC”) of $250,000. As of December 31, 2023, of the total $2.1 million in cash and cash equivalents, $36,000 was held by foreign subsidiaries. As of December 31, 2022, of the total $7.0 million in cash and cash equivalents, $0.4 million was held by foreign subsidiaries. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2100000
CY2023Q4	nwbo	Cash And Cash Equivalents Held By Foreign Subsidiaries CashAndCashEquivalentsHeldByForeignSubsidiaries	36000
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	7000000.0
CY2022Q4	nwbo	Cash And Cash Equivalents Held By Foreign Subsidiaries CashAndCashEquivalentsHeldByForeignSubsidiaries	400000
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2023	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Derivative Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expense), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.</p>
CY2023	nwbo	Modification Of Equity Classified Warrants ModificationOfEquityClassifiedWarrants	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Modification of Equity Classified Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A change in the terms or conditions of a warrant is accounted for as a modification. For a warrant modification accounted for under ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over and the fair value of the original warrant immediately before its terms are modified, with each measured on the modification date. The accounting for any incremental fair value of the modified warrants over the original warrants is based on the specific facts and circumstances related to the modification. When a modification is directly attributable to an equity offering, the incremental change in fair value of the warrants is accounted for as an equity issuance cost. When a modification is directly attributable to a debt financing, the incremental change in fair value of the warrants is accounted for as a debt discount or debt issuance cost. For all other modifications, the incremental change in fair value is recognized as a deemed dividend.</p>
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	944000
CY2023Q4	nwbo	Contingent Payable Derivative Liability ContingentPayableDerivativeLiability	9188000
CY2023Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	12771000
CY2023Q4	nwbo	Share Liability ShareLiability	483000
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	23386000
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	80559000
CY2022Q4	nwbo	Embedded Derivative Redemption Option Fair Value Of Embedded Derivative Liability EmbeddedDerivativeRedemptionOptionFairValueOfEmbeddedDerivativeLiability	807000
CY2022Q4	nwbo	Contingent Payable Derivative Liability ContingentPayableDerivativeLiability	8668000
CY2022Q4	nwbo	Share Liability ShareLiability	678000
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	90712000
CY2023	nwbo	Fair Value Liabilities Transfer Between Levels Amount FairValueLiabilitiesTransferBetweenLevelsAmount	0
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	116004000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	191000
CY2022	nwbo	Fair Value Of Additional Share Liability FairValueOfAdditionalShareLiability	711000
CY2022	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Debt Redemption FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDebtRedemption	-213000
CY2022	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification For Warrants Exercised For Cash FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash	51769000
CY2022	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	25788000
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	90712000
CY2023	nwbo	Fair Value Of Additional Share Liability FairValueOfAdditionalShareLiability	818000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	10750000
CY2023	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Debt Redemption FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDebtRedemption	-1091000
CY2023	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification For Warrants Exercised For Cash FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash	76258000
CY2023	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-1545000
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	23386000
CY2023Q4	nwbo	Warrant Liability Related To Purchase Shares In Future Raise Of Capital WarrantLiabilityRelatedToPurchaseSharesInFutureRaiseOfCapital	900000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4408000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12298000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15571000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3600000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.51
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.65
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.92
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M24D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y10M24D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.86
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.99
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.97
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.045
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.033
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.010
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4700000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	308840000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.33
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	372219000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	910000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.92
CY2021	nwbo	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P8Y7M6D
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	183000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.25
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	4720000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.25
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	304847000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.33
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	114803000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8005000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.65
CY2022	nwbo	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P4Y4M24D
CY2022	nwbo	Stock Issued During Period Shares Stock Options Cash Exercised StockIssuedDuringPeriodSharesStockOptionsCashExercised	8187000
CY2022	nwbo	Sharebasedcompensationarrangementsbysharebasedpaymentawardoptions Cash Exercises In Period Weighted Average Exercise Price SharebasedcompensationarrangementsbysharebasedpaymentawardoptionsCashExercisesInPeriodWeightedAverageExercisePrice	0.27
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3402000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.88
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	301263000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.34
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	135225000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	20220000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.51
CY2023	nwbo	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P6Y
CY2023	nwbo	Stock Issued During Period Shares Stock Options Cash Exercised StockIssuedDuringPeriodSharesStockOptionsCashExercised	150000
CY2023	nwbo	Sharebasedcompensationarrangementsbysharebasedpaymentawardoptions Cash Exercises In Period Weighted Average Exercise Price SharebasedcompensationarrangementsbysharebasedpaymentawardoptionsCashExercisesInPeriodWeightedAverageExercisePrice	0.25
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3857000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.36
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	400000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.83
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	317076000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.35
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	114097000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	280023000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.33
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	104780000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	20200000
CY2023	nwbo	Share Based Compensation Arrangement By Share Based Payment Award Period Of Notice For Exercising Any Option ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfNoticeForExercisingAnyOption	P61D
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17278000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13418000
CY2023	us-gaap	Depreciation Depreciation	1500000
CY2023	us-gaap	Depreciation Depreciation	1500000
CY2022	us-gaap	Depreciation Depreciation	1300000
CY2021	us-gaap	Depreciation Depreciation	300000
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	40769000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1998000
CY2023Q4	nwbo	Fair Value Of Embedded Conversion Option FairValueOfEmbeddedConversionOption	2021000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	40792000
CY2023	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	1100000
CY2023	nwbo	Accrued Share Liabilities AccruedShareLiabilities	800000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	5400000
CY2023Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	800000
CY2023	us-gaap	Interest And Debt Expense InterestAndDebtExpense	5200000
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2400000
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	22454000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1732000
CY2022Q4	nwbo	Fair Value Of Embedded Conversion Option FairValueOfEmbeddedConversionOption	807000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	21529000
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	22000
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	407000
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	223000
CY2023	us-gaap	Interest Expense InterestExpense	5241000
CY2022	us-gaap	Interest Expense InterestExpense	6068000
CY2021	us-gaap	Interest Expense InterestExpense	5011000
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	40769000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-105032000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	179126000
CY2021	nwbo	Reversal Of Gain Due To Change In Fair Value Of Warrant Liability ReversalOfGainDueToChangeInFairValueOfWarrantLiability	-239347000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-62599000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-105032000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-60221000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1119191
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1015852
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	873517
CY2021	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	76
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1119191
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1015852
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1007869
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	486917000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	477773000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	396039000
CY2023	nwbo	Percentage Of Margin PercentageOfMargin	0.15
CY2023	nwbo	Ancillary Services Agreement Additional Term Of Agreement AncillaryServicesAgreementAdditionalTermOfAgreement	P12M
CY2023	nwbo	Payment Of Milestones In Cash PaymentOfMilestonesInCash	5000000.0
CY2023	nwbo	Amount Recognized And Expensed Related To Current Cash Component AmountRecognizedAndExpensedRelatedToCurrentCashComponent	1000000.0
CY2023	nwbo	Number Of Milestones Completed NumberOfMilestonesCompleted	2
CY2023	nwbo	Partial Payment For Milestone Completed PartialPaymentForMilestoneCompleted	4000000.0
CY2023	nwbo	Shares Issued For Completion Of Milestone SharesIssuedForCompletionOfMilestone	4500000
CY2023Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	3200000
CY2023	nwbo	Stock Based Compensation Related To Achieved Milestone StockBasedCompensationRelatedToAchievedMilestone	600000
CY2022	nwbo	Stock Based Compensation Related To Achieved Milestone StockBasedCompensationRelatedToAchievedMilestone	2600000
CY2022	us-gaap	Sublease Income SubleaseIncome	145000
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1400000
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.24
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	329000
CY2022Q3	nwbo	Term By Which Preferred Shares Cannot Be Converted Into Common Stock TermByWhichPreferredSharesCannotBeConvertedIntoCommonStock	P3M
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1400000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1200000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1700000000
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	nwbo	Proceeds From Investor Advances ProceedsFromInvestorAdvances	1200000
CY2023	nwbo	Stock Issued During Period Shares Warrant Exercises StockIssuedDuringPeriodSharesWarrantExercises	12800000
CY2023	nwbo	Number Of Options Cash Less Exercise NumberOfOptionsCashLessExercise	3900000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11100000
CY2022	nwbo	Stock Issued During Period Shares Warrant Exercises StockIssuedDuringPeriodSharesWarrantExercises	45300000
CY2023	nwbo	Debt Instrument Redemption Shares Issued DebtInstrumentRedemptionSharesIssued	18100000
CY2023	nwbo	Debt Instrument Redemption Amount DebtInstrumentRedemptionAmount	11300000
CY2023	nwbo	Debt Instrument Redemption Amount Interest DebtInstrumentRedemptionAmountInterest	1800000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	20000000.0
CY2021	nwbo	Stock Issued During Period Shares Warrant Exercises StockIssuedDuringPeriodSharesWarrantExercises	86900000
CY2021	nwbo	Debt Instrument Percentage Of Aggregate Principal Amount For Next Offering DebtInstrumentPercentageOfAggregatePrincipalAmountForNextOffering	0.50
CY2021	nwbo	Debt Instrument Discount Rate DebtInstrumentDiscountRate	0.12
CY2021	nwbo	Inducement Expense InducementExpense	600000
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	331753
CY2020Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.28
CY2020	nwbo	Class Of Warrant Or Right Outstanding Remaining Contractual Term ClassOfWarrantOrRightOutstandingRemainingContractualTerm	P1Y7M9D
CY2021	nwbo	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	1209
CY2021Q4	nwbo	Classofwarrant Or Right Granted Weighted Average Exercise Price ClassofwarrantOrRightGrantedWeightedAverageExercisePrice	1.39
CY2021	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	86726
CY2021	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	0.23
CY2021	nwbo	Number Of Warrants Warrants Cashless Exercise NumberOfWarrantsWarrantsCashlessExercise	19743
CY2021	nwbo	Weighted Average Exercise Price Warrants Cashless Exercise WeightedAverageExercisePriceWarrantsCashlessExercise	0.22
CY2021	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	1024
CY2021	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	2.95
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	225469
CY2021Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.30
CY2021	nwbo	Class Of Warrant Or Right Outstanding Remaining Contractual Term ClassOfWarrantOrRightOutstandingRemainingContractualTerm	P0Y11M15D
CY2022	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	46671
CY2022	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	0.25
CY2022	nwbo	Number Of Warrants Warrants Cashless Exercise NumberOfWarrantsWarrantsCashlessExercise	35951
CY2022	nwbo	Weighted Average Exercise Price Warrants Cashless Exercise WeightedAverageExercisePriceWarrantsCashlessExercise	0.23
CY2022	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	1799
CY2022	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	1.58
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	141048
CY2022Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.31
CY2022	nwbo	Class Of Warrant Or Right Outstanding Remaining Contractual Term ClassOfWarrantOrRightOutstandingRemainingContractualTerm	P1Y5M15D
CY2023	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	12650
CY2023	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	0.23
CY2023	nwbo	Number Of Warrants Warrants Cashless Exercise NumberOfWarrantsWarrantsCashlessExercise	22907
CY2023	nwbo	Weighted Average Exercise Price Warrants Cashless Exercise WeightedAverageExercisePriceWarrantsCashlessExercise	0.20
CY2023	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	250
CY2023	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	1.36
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	105241
CY2023Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.31
CY2023	nwbo	Class Of Warrant Or Right Outstanding Remaining Contractual Term ClassOfWarrantOrRightOutstandingRemainingContractualTerm	P1Y9M29D
CY2023	nwbo	Class Of Warrant Or Right Extended In Suspension ClassOfWarrantOrRightExtendedInSuspension	94000000
CY2023	nwbo	Share Based Payment Arrangement Plan Modification Associated With Debt Financing As Additional Debt Discount ShareBasedPaymentArrangementPlanModificationAssociatedWithDebtFinancingAsAdditionalDebtDiscount	700000
CY2023	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	1800000
CY2023Q4	us-gaap	Lease Practical Expedient Lessor Single Lease Component LeasePracticalExpedientLessorSingleLeaseComponent	true
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4800000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4200000
CY2023	nwbo	Office Space Taken Under Lease Agreement OfficeSpaceTakenUnderLeaseAgreement	The Company subleased approximately 14,459 square feet of 88,000 square foot building interior space, plus corresponding exterior support space and parking located in Sawston, UK. Lease payments under the Agreement are two times the £5.75 (approximate $7.32 per square foot based on exchange rate as of December 31, 2023) rate per square foot payable under the head lease, subject to a cap of $10 per square foot. Accordingly, the lease payments under the Sublease are set at $145,000 per year. The total lease payments paid by the Company for the overall building, exterior space and parking under the head lease were £500,000 (approximate $637,000), and were increased to £520,000 (approximate $662,000) per year effective December 25, 2023.
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	850000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	74000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	15000
CY2023	us-gaap	Sublease Income SubleaseIncome	144000
CY2023	us-gaap	Lease Cost LeaseCost	794000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	846000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	848000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	79000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	13000
CY2022	us-gaap	Sublease Income SubleaseIncome	145000
CY2022	us-gaap	Lease Cost LeaseCost	795000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	909000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	930000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	51000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	53000
CY2021	us-gaap	Lease Cost LeaseCost	1034000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	866000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	867000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	662000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	662000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	662000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	662000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6600000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10115000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5347000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4768000
CY2022Q2	nwbo	Received Tax Bills ReceivedTaxBills	222000
CY2022Q2	nwbo	Received Tax Bills ReceivedTaxBills	245000
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	188000
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	207000
CY2023Q4	us-gaap	Loss Contingency Accrual Payments LossContingencyAccrualPayments	189000
CY2023Q4	us-gaap	Loss Contingency Accrual Payments LossContingencyAccrualPayments	208000
CY2023Q4	nwbo	Accrued Income Tax Liability Trade Tax AccruedIncomeTaxLiabilityTradeTax	155000
CY2023Q4	nwbo	Accrued Income Tax Liability Trade Tax AccruedIncomeTaxLiabilityTradeTax	171000
CY2023Q4	nwbo	Accrued Income Tax Liability Corporation Tax AccruedIncomeTaxLiabilityCorporationTax	98000
CY2023Q4	nwbo	Accrued Income Tax Liability Corporation Tax AccruedIncomeTaxLiabilityCorporationTax	108000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	211533000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	202525000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	18377000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	17989000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	15712000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	18021000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	15823000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	9144000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	261445000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	247679000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	261445000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	247679000
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	739700000
CY2023Q4	nwbo	Deferred Tax Assets Tax Credit Carry Forward Unused Research And Development DeferredTaxAssetsTaxCreditCarryForwardUnusedResearchAndDevelopment	519500000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	18400000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	39300000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.058
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.046
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.002
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.012
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.052
CY2023	nwbo	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLosses	0.035
CY2022	nwbo	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLosses	0.026
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.046
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.060
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.006
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.015
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.220
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.117
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-9859000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8868000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3927000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3097000
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	19000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-489000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-13767000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-12454000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0

Files In Submission

Name	View Source	Status
0001410578-24-000133-index-headers.html	Edgar Link	pending
0001410578-24-000133-index.html	Edgar Link	pending
0001410578-24-000133.txt	Edgar Link	pending
0001410578-24-000133-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nwbo-20231231.xsd	Edgar Link	pending
nwbo-20231231x10k.htm	Edgar Link	pending
nwbo-20231231x10k001.jpg	Edgar Link	pending
nwbo-20231231xex10d89.htm	Edgar Link	pending
nwbo-20231231xex10d90.htm	Edgar Link	pending
nwbo-20231231xex23d1.htm	Edgar Link	pending
nwbo-20231231xex31d1.htm	Edgar Link	pending
nwbo-20231231xex32d1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nwbo-20231231_cal.xml	Edgar Link	unprocessable
nwbo-20231231_def.xml	Edgar Link	unprocessable
nwbo-20231231_lab.xml	Edgar Link	unprocessable
nwbo-20231231_pre.xml	Edgar Link	unprocessable
nwbo-20231231x10k_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2024 Q1 Form 10-K Financial Statement

#000141057824000133 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2024 Q1 Form 10-K Financial Statement

#000141057824000133 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo